GlassScriptPhysician profile
Kimberly A Clay
NPI 1447346887
$10,523.07
in general payments reported to CMS, 2019-2025
29 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,704 · 2022: $2,982 · 2023: $2,476 · 2024: $1,431 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.89 |
| Education | $153.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,516.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,516.48 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Biocryst US Sales Co., LLC | $1,294.71 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $1,202.55 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $847.42 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $779.23 | 2021-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $734.85 | 2021-2025 | Dupixent |
| Covis Pharma Gmbh | $407.19 | 2021-2023 | |
| Grifols USA, LLC | $284.72 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $270.90 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $220.84 | 2021-2025 | |
| Octapharma USA, INC. | $214.97 | 2022-2024 | Cutaquig |
| Pfizer INC. | $182.95 | 2021-2023 | |
| Kaleo, INC. | $150.53 | 2021-2023 | Auvi-Q |
| Amgen INC. | $138.42 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $111.53 | 2021-2023 | |
| Pharming Healthcare, INC. | $96.75 | 2022-2024 | Ruconest |
| Ionis Pharmaceuticals, INC. | $92.53 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.32 | 2021-2023 | Ofev |
| Abbvie INC. | $55.26 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $54.70 | 2025 | Neffy |
| Genentech USA, INC. | $53.49 | 2022 | |
| Aimmune Therapeutics, INC. | $40.52 | 2022 | |
| Cycle Pharmaceuticals INC | $39.39 | 2024 | Sajazir |
| Alk-Abello, INC | $36.12 | 2021 | |
| Merck Sharp & Dohme LLC | $29.92 | 2021-2023 | |
| Blueprint Medicines Corporation | $27.95 | 2024 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $18.75 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $18.12 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.